These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14600842)

  • 41. Structure-activity study of pentamidine analogues as antiprotozoal agents.
    Bakunova SM; Bakunov SA; Patrick DA; Kumar EV; Ohemeng KA; Bridges AS; Wenzler T; Barszcz T; Jones SK; Werbovetz KA; Brun R; Tidwell RR
    J Med Chem; 2009 Apr; 52(7):2016-35. PubMed ID: 19267462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents.
    Meng Q; Luo H; Liu Y; Li W; Zhang W; Yao Q
    Bioorg Med Chem Lett; 2009 May; 19(10):2808-10. PubMed ID: 19362471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-African trypanocidal and antimalarial activity of natural flavonoids, dibenzoylmethanes and synthetic analogues.
    dos Santos DA; de C Braga PA; da Silva MF; Fernandes JB; Vieira PC; Magalhães AF; Magalhães EG; Marsaioli AJ; de S Moraes VR; Rattray L; Croft SL
    J Pharm Pharmacol; 2009 Feb; 61(2):257-66. PubMed ID: 19178775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
    Mäntylä A; Garnier T; Rautio J; Nevalainen T; Vepsälainen J; Koskinen A; Croft SL; Järvinen T
    J Med Chem; 2004 Jan; 47(1):188-95. PubMed ID: 14695832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A small library of trisubstituted pyrimidines as antimalarial and antitubercular agents.
    Agarwal A; Srivastava K; Puri SK; Sinha S; Chauhan PM
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5218-21. PubMed ID: 16171994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic justification of antiprotozoal therapy. A US perspective.
    Berman JD; Fleckenstein L
    Clin Pharmacokinet; 1991 Dec; 21(6):479-93. PubMed ID: 1782741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymeric prodrugs.
    Hoste K; De Winne K; Schacht E
    Int J Pharm; 2004 Jun; 277(1-2):119-31. PubMed ID: 15158975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Azaterphenyl diamidines as antileishmanial agents.
    Hu L; Arafa RK; Ismail MA; Wenzler T; Brun R; Munde M; Wilson WD; Nzimiro S; Samyesudhas S; Werbovetz KA; Boykin DW
    Bioorg Med Chem Lett; 2008 Jan; 18(1):247-51. PubMed ID: 18006310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis.
    Buckner FS; Eastman RT; Yokoyama K; Gelb MH; Van Voorhis WC
    Curr Opin Investig Drugs; 2005 Aug; 6(8):791-7. PubMed ID: 16121685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
    Peppard WJ; Schuenke CD
    Curr Opin Investig Drugs; 2008 Feb; 9(2):210-25. PubMed ID: 18246524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The assessment of new anti-tuberculosis drugs for a paediatric indication.
    Donald PR
    Int J Tuberc Lung Dis; 2007 Nov; 11(11):1162-5. PubMed ID: 17958976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advancing the science in clinical trials for new TB drugs.
    Burman W; McNeeley D; Moulton LH; Spigelman M; Vernon A
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):111-2. PubMed ID: 18230241
    [No Abstract]   [Full Text] [Related]  

  • 53. Evidences for the formation of bisbenzamidine-heme complexes in cell-free systems.
    Mayence A; Vanden Eynde JJ; Huang TL
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1625-8. PubMed ID: 15026037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of azasterols as anti-parasitics.
    Gros L; Lorente SO; Jimenez CJ; Yardley V; Rattray L; Wharton H; Little S; Croft SL; Ruiz-Perez LM; Gonzalez-Pacanowska D; Gilbert IH
    J Med Chem; 2006 Oct; 49(20):6094-103. PubMed ID: 17004723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apixaban, an oral, direct inhibitor of activated Factor Xa.
    Shantsila E; Lip GY
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1020-33. PubMed ID: 18729009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are cataract and iris atrophy toxic complications of medical treatment of acanthamoeba keratitis?
    Ehlers N; Hjortdal J
    Acta Ophthalmol Scand; 2004 Apr; 82(2):228-31. PubMed ID: 15043548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
    Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
    J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Technology evaluation: FluINsure, ID Biomedical.
    Munoz FM
    Curr Opin Mol Ther; 2004 Apr; 6(2):212-20. PubMed ID: 15195934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of antiprotozoal and plasmodial enoyl-ACP reductase inhibition potential of turkish medicinal plants.
    Tasdemir D; Brun R; Perozzo R; Dönmez AA
    Phytother Res; 2005 Feb; 19(2):162-6. PubMed ID: 15852483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.